The purpose of this study is to compare the effectiveness of bortezomib versus thalidomide in
reducing free light chains in the blood of myeloma patients. In addition participants will
receive bendamustine (chemotherapy) and dexamethasone (steroids), which increase the
effectiveness of both bortezomib and thalidomide. The trial will also study whether an
earlier reduction of free light chains increases the chances of the kidneys recovering.
Phase:
Phase 2
Details
Lead Sponsor:
Oxford University Hospitals NHS Trust
Collaborators:
Bloodwise Janssen-Cilag Ltd. Napp Pharmaceuticals Limited University of Birmingham University of Warwick Warwick Medical School